Skip to content
Regulations & Compliance

IND (investigational new drug)

An application submitted to the FDA before human clinical trials can begin. The IND includes preclinical data, manufacturing information, and the proposed clinical trial protocol.

Frequently Asked Questions

What is IND (investigational new drug)?
An application submitted to the FDA before human clinical trials can begin. The IND includes preclinical data, manufacturing information, and the proposed clinical trial protocol.
Why is IND (investigational new drug) important in peptide research?
Understanding ind (investigational new drug) is crucial for navigating the legal and regulatory landscape of peptide use. Regulatory knowledge helps practitioners and patients distinguish between approved therapies, compounded medications, and research chemicals.

Related Terms

Clinical trial phases

The staged process of testing a new drug in humans: Phase 1 (safety), Phase 2 (efficacy), Phase 3 (large-scale confirmation), and Phase 4 (post-marketing surveillance). Each phase has specific objectives and requirements.

NDA (new drug application)

The formal application to the FDA requesting approval to market a new drug. Contains all clinical trial data, manufacturing details, and proposed labeling. Review takes 6–12 months.

Preclinical

The research stage involving in vitro (cell culture) and in vivo (animal) studies before human clinical trials begin. Most peptides outside GLP-1 agonists remain at this evidence stage.

← Back to full glossary